Maria Learoyd
Cambridge, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
Safety and Pharmacokinetics of Nirsevimab in Japanese Infants: Primary Analysis of the Open-Label JUBILUS Trial.
Journal: Journal of the Pediatric Infectious Diseases Society
Published: July 09, 2025
Effect of food on selumetinib pharmacokinetics and gastrointestinal tolerability in adolescents with neurofibromatosis type 1-related plexiform neurofibromas.
Journal: Neuro-oncology advances
Published: May 09, 2024
Pharmacokinetics and safety of olaparib in patients with advanced solid tumours and mild or moderate hepatic impairment.
Journal: British journal of clinical pharmacology
Published: November 04, 2019
Pharmacokinetics and Safety of Olaparib in Patients with Advanced Solid Tumours and Renal Impairment.
Journal: Clinical pharmacokinetics
Published: March 17, 2019
Bridging Olaparib Capsule and Tablet Formulations Using Population Pharmacokinetic Meta-analysis in Oncology Patients.
Journal: Clinical pharmacokinetics
Published: October 26, 2018
Efficacy and Safety Exposure-Response Analyses of Olaparib Capsule and Tablet Formulations in Oncology Patients.
Journal: Clinical pharmacology and therapeutics
Published: September 14, 2018
Pharmacokinetic Effects and Safety of Olaparib Administered with Endocrine Therapy: A Phase I Study in Patients with Advanced Solid Tumours.
Journal: Advances in therapy
Published: August 13, 2018
Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial.
Journal: The Lancet. Oncology
Published: April 06, 2018
Physiologically Based Pharmacokinetic Modeling for Olaparib Dosing Recommendations: Bridging Formulations, Drug Interactions, and Patient Populations.
Journal: Clinical pharmacology and therapeutics
Published: January 26, 2018
In vitro evaluation of the inhibition and induction potential of olaparib, a potent poly(ADP-ribose) polymerase inhibitor, on cytochrome P450.
Journal: Xenobiotica; the fate of foreign compounds in biological systems
Published: June 29, 2017
A Randomized, Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of Ceftazidime-Avibactam in Healthy Chinese Subjects.
Journal: Clinical drug investigation
Published: December 10, 2015
Randomized pharmacokinetic and drug-drug interaction studies of ceftazidime, avibactam, and metronidazole in healthy subjects.
Journal: Pharmacology research & perspectives
Published: June 23, 2015
Last Updated: 09/26/2026